Related Experiment Video
Updated: Mar 17, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
miR-646 is a key negative regulator of EGFR pathway in lung cancer
Yunhu Pan1,2, Yitan Chen2, Debin Ma3
1a Department of Respiratory and Critical Care Medicine, Changhai Hospital , Second Military Medical University , Yangpu District , Shanghai , China.
Background:
As one of the leading cause of cancer-related deaths in the worldwide, lung cancer needs to be understood better. Nowadays, increasing point mutations of specific oncogenes are biomarkers used to predict the therapeutic effect of targeted therapy and lung cancer has entered the age of individual treatment. At present, many relevant researchers have suggested that EGFR is a biomarker used to predict the therapeutic effect of targeted therapy. A large number of evidence indicates that EGFR/Akt pathway plays important role in cancer growth and metastasis.
Aim Of The Study:
In this paper, we found EGFR was a target of miR-646.
Results:
Overexpression of miR-646 not only downregulated EGFR/Akt pathway, but also inhibited lung cancer cell proliferation and metastasis. At the same time, miR-646 was a prognosis factor for overall survival.
Conclusion:
Our finding could provide new insights into the molecular therapeutic of lung cancer.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
MicroRNAs
MicroRNAs
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Master Transcription Regulators

